跳至主要内容
临床试验/JPRN-UMIN000000720
JPRN-UMIN000000720已完成3 期

A Phase III Randomized, Multicenter Study Comparing Irinotevan and Cisplatin (IP) with Amrubicin and Cisplatin (AP) for the Treatment of Extensive-Stage Small-Cell Lung Cancer: (JCOG0509) - A Phase III Randomized, Multicenter Study Comparing Irinotevan and Cisplatin (IP) with Amrubicin and Cisplatin (AP) for the Treatment of Extensive-Stage Small-Cell Lung Cancer: (JCOG0509)

Japan Clinical Oncology Group(JCOG)0 个研究点目标入组 282 人开始时间: 2007年5月22日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
282

研究概览

简要总结

See the datails via "URL releasing results" above. Also the details can be seen in the JCOG website: http://www.jcog.jp/en/trials/index.html

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 70years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) active concomitant malignancy 2) severe complications related malignancy (Superior vena cava syndrome, pleural effusion that required drainage, pericarditis carcinomatous, symptomatic brain metastasis) 3) active infection 4) watery diarrhea 5) intestinal obstruction or paralysis 6) interstitial pneumonia/active lung fibrosis on chest x-ray 7) non-steroidal anti-inflammatory drug or glucocorticoid use for >50 days 8) uncontrolled diabetes mellitus, 9) uncontrolled heart disease or a history of myocardial infarction within the previous 6 months 10) psychological disease deemed unacceptable for inclusion to the study 11) pregnant or lactating women 12) active gastric and/or duodenal ulcer

研究者

发起方
Japan Clinical Oncology Group(JCOG)

相似试验